Topcon Healthcare has signed a definitive agreement to acquire New Zealand-founded AI health-technology company Toku Eyes, now based in San Diego. The acquisition is part of the integration of Toku’s retinal-image AI platforms – MyKidneyAI, CLAiR and BioAge – into its ‘Healthcare from the Eye’ ecosystem.
The financial terms of the acquisition were not disclosed.
Under the arrangement, standard retinal images will be used to provide real-time assessments of biological age, cardiovascular risk and chronic kidney disease risk. In September 2025, Optos announced a partnership with Toku to integrate BioAge into its ultra-widefield retinal imaging devices.
A Topcon statement said its Harmony digital platform aims to enable cloud-based AI health assessments across primary care, eyecare and telehealth environments, making predictive and preventive screening widely accessible.
In the acquisition announcement, Toku reported having analysed more than 4.3 million de-identified retinal images linked to clinical data to power its predictive models and support earlier detection of elevated disease risk before symptoms emerge. Kate Blackbourn, Toku’s chief product officer, could not say in time for publication if anonymised BioAge data would be shared with US insurers.
